| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 26 | 2025 | 995 | 2.230 |
Why?
|
| Liver Neoplasms | 27 | 2025 | 1382 | 1.980 |
Why?
|
| Liver Cirrhosis | 17 | 2025 | 913 | 1.450 |
Why?
|
| Veterans | 37 | 2026 | 1788 | 1.340 |
Why?
|
| alpha-Fetoproteins | 10 | 2020 | 136 | 1.290 |
Why?
|
| Hepatitis C, Chronic | 11 | 2025 | 367 | 1.250 |
Why?
|
| Hepatitis C | 13 | 2018 | 389 | 1.110 |
Why?
|
| Renal Insufficiency, Chronic | 7 | 2023 | 849 | 0.960 |
Why?
|
| Antiviral Agents | 8 | 2025 | 806 | 0.940 |
Why?
|
| Interferons | 1 | 2025 | 136 | 0.830 |
Why?
|
| United States Department of Veterans Affairs | 19 | 2026 | 726 | 0.780 |
Why?
|
| Barrett Esophagus | 10 | 2013 | 360 | 0.740 |
Why?
|
| United States | 57 | 2026 | 11877 | 0.730 |
Why?
|
| Algorithms | 11 | 2020 | 1678 | 0.720 |
Why?
|
| Middle Aged | 88 | 2026 | 28448 | 0.700 |
Why?
|
| HIV Infections | 13 | 2025 | 2037 | 0.690 |
Why?
|
| Subacute Care | 2 | 2018 | 8 | 0.660 |
Why?
|
| Creatinine | 1 | 2021 | 397 | 0.620 |
Why?
|
| Aged | 65 | 2026 | 20928 | 0.590 |
Why?
|
| Glomerular Filtration Rate | 2 | 2021 | 568 | 0.590 |
Why?
|
| Quality Improvement | 5 | 2026 | 700 | 0.580 |
Why?
|
| Colorectal Neoplasms | 5 | 2017 | 623 | 0.560 |
Why?
|
| Hepatitis B, Chronic | 5 | 2022 | 88 | 0.550 |
Why?
|
| International Classification of Diseases | 6 | 2018 | 98 | 0.530 |
Why?
|
| Colorectal Surgery | 1 | 2017 | 13 | 0.520 |
Why?
|
| Gastroesophageal Reflux | 9 | 2013 | 334 | 0.510 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2022 | 750 | 0.510 |
Why?
|
| Male | 92 | 2026 | 64498 | 0.490 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 263 | 0.490 |
Why?
|
| Proton Pump Inhibitors | 6 | 2017 | 282 | 0.490 |
Why?
|
| Veterans Health | 3 | 2025 | 172 | 0.470 |
Why?
|
| Cohort Studies | 29 | 2025 | 5081 | 0.470 |
Why?
|
| Female | 87 | 2026 | 70401 | 0.450 |
Why?
|
| Surgical Procedures, Operative | 3 | 2026 | 224 | 0.450 |
Why?
|
| Humans | 116 | 2026 | 130496 | 0.440 |
Why?
|
| Decision Support Techniques | 3 | 2015 | 296 | 0.430 |
Why?
|
| Histamine H2 Antagonists | 2 | 2017 | 49 | 0.420 |
Why?
|
| Risk Factors | 32 | 2025 | 10959 | 0.410 |
Why?
|
| Quality Indicators, Health Care | 3 | 2024 | 240 | 0.400 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2021 | 409 | 0.390 |
Why?
|
| Head and Neck Neoplasms | 3 | 2025 | 633 | 0.380 |
Why?
|
| Retrospective Studies | 42 | 2025 | 17554 | 0.370 |
Why?
|
| Hepatitis B | 3 | 2021 | 173 | 0.370 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2013 | 298 | 0.350 |
Why?
|
| Serum | 1 | 2011 | 43 | 0.350 |
Why?
|
| Hospitals, Veterans | 5 | 2021 | 345 | 0.350 |
Why?
|
| Anus Neoplasms | 3 | 2021 | 42 | 0.350 |
Why?
|
| Anti-Ulcer Agents | 3 | 2009 | 113 | 0.350 |
Why?
|
| Colitis, Ulcerative | 5 | 2017 | 213 | 0.340 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2018 | 328 | 0.340 |
Why?
|
| Esophageal Neoplasms | 5 | 2019 | 392 | 0.330 |
Why?
|
| Adult | 49 | 2025 | 31183 | 0.320 |
Why?
|
| Alanine Transaminase | 3 | 2018 | 157 | 0.320 |
Why?
|
| Azetidines | 2 | 2021 | 63 | 0.320 |
Why?
|
| Hospital Mortality | 6 | 2023 | 1064 | 0.320 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 6812 | 0.290 |
Why?
|
| Hepatitis B virus | 4 | 2022 | 135 | 0.290 |
Why?
|
| Risk Assessment | 11 | 2025 | 3680 | 0.290 |
Why?
|
| Gulf War | 2 | 2025 | 10 | 0.280 |
Why?
|
| Protease Inhibitors | 2 | 2021 | 95 | 0.280 |
Why?
|
| Sulfonamides | 2 | 2021 | 298 | 0.280 |
Why?
|
| Hospitals | 4 | 2024 | 441 | 0.270 |
Why?
|
| Incidence | 16 | 2022 | 3327 | 0.270 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2023 | 217 | 0.270 |
Why?
|
| Case-Control Studies | 18 | 2021 | 3380 | 0.260 |
Why?
|
| Hospitalization | 6 | 2021 | 1929 | 0.260 |
Why?
|
| Crohn Disease | 4 | 2017 | 292 | 0.260 |
Why?
|
| Logistic Models | 12 | 2021 | 1811 | 0.260 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2023 | 140 | 0.250 |
Why?
|
| Population Surveillance | 4 | 2021 | 397 | 0.250 |
Why?
|
| Age Factors | 8 | 2019 | 2839 | 0.250 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 776 | 0.250 |
Why?
|
| Patient Compliance | 1 | 2009 | 461 | 0.240 |
Why?
|
| Hepacivirus | 3 | 2013 | 274 | 0.230 |
Why?
|
| Prognosis | 11 | 2026 | 4880 | 0.230 |
Why?
|
| Mass Screening | 6 | 2018 | 814 | 0.230 |
Why?
|
| Cardiovascular Diseases | 5 | 2023 | 2105 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2025 | 33 | 0.220 |
Why?
|
| Atherosclerosis | 2 | 2025 | 951 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 640 | 0.220 |
Why?
|
| Postoperative Complications | 4 | 2024 | 3110 | 0.210 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2026 | 147 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2025 | 138 | 0.210 |
Why?
|
| Electronic Health Records | 5 | 2026 | 817 | 0.200 |
Why?
|
| Proportional Hazards Models | 8 | 2026 | 1397 | 0.200 |
Why?
|
| Monocytes | 1 | 2026 | 337 | 0.200 |
Why?
|
| Persian Gulf Syndrome | 1 | 2023 | 16 | 0.200 |
Why?
|
| Natural Language Processing | 2 | 2016 | 76 | 0.200 |
Why?
|
| Purines | 2 | 2021 | 115 | 0.200 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2019 | 137 | 0.190 |
Why?
|
| Angioedema | 1 | 2023 | 22 | 0.190 |
Why?
|
| Databases, Factual | 4 | 2020 | 1228 | 0.190 |
Why?
|
| Body Mass Index | 3 | 2018 | 1679 | 0.190 |
Why?
|
| Quality Assurance, Health Care | 2 | 2021 | 207 | 0.190 |
Why?
|
| Survival Analysis | 6 | 2017 | 1492 | 0.180 |
Why?
|
| Hyperlipidemias | 1 | 2023 | 188 | 0.180 |
Why?
|
| HIV | 2 | 2020 | 176 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 742 | 0.170 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2021 | 36 | 0.170 |
Why?
|
| Perioperative Period | 1 | 2021 | 51 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 424 | 0.170 |
Why?
|
| Pyrazoles | 2 | 2021 | 357 | 0.170 |
Why?
|
| Prevalence | 12 | 2021 | 2699 | 0.170 |
Why?
|
| Janus Kinases | 1 | 2021 | 36 | 0.160 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 124 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 264 | 0.160 |
Why?
|
| Predictive Value of Tests | 7 | 2018 | 2300 | 0.160 |
Why?
|
| Reproducibility of Results | 7 | 2018 | 2908 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 813 | 0.160 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 5177 | 0.160 |
Why?
|
| Registries | 7 | 2019 | 1612 | 0.150 |
Why?
|
| Anti-HIV Agents | 1 | 2022 | 353 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 749 | 0.140 |
Why?
|
| Cross-Sectional Studies | 11 | 2026 | 3807 | 0.140 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 141 | 0.140 |
Why?
|
| Alcohol Drinking | 3 | 2019 | 341 | 0.140 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 643 | 0.140 |
Why?
|
| Odds Ratio | 6 | 2021 | 1216 | 0.140 |
Why?
|
| Length of Stay | 3 | 2021 | 1395 | 0.140 |
Why?
|
| Gout | 1 | 2021 | 172 | 0.140 |
Why?
|
| Platelet Count | 2 | 2018 | 138 | 0.140 |
Why?
|
| Outpatients | 2 | 2013 | 265 | 0.140 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2018 | 32 | 0.140 |
Why?
|
| Time Factors | 6 | 2025 | 6206 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 562 | 0.140 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 37 | 0.140 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 129 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 385 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2020 | 637 | 0.130 |
Why?
|
| Virus Activation | 1 | 2018 | 86 | 0.130 |
Why?
|
| Colonoscopy | 2 | 2012 | 242 | 0.130 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 892 | 0.130 |
Why?
|
| Adipokines | 1 | 2018 | 120 | 0.130 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 134 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 126 | 0.130 |
Why?
|
| Treatment Outcome | 10 | 2022 | 12850 | 0.130 |
Why?
|
| Gastric Acid | 1 | 2017 | 55 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.130 |
Why?
|
| Hypertension | 2 | 2023 | 1349 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2017 | 86 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2020 | 231 | 0.120 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2013 | 230 | 0.120 |
Why?
|
| Sensitivity and Specificity | 7 | 2018 | 2105 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 63 | 0.120 |
Why?
|
| Drug Prescriptions | 2 | 2010 | 230 | 0.120 |
Why?
|
| Liver | 2 | 2021 | 1793 | 0.120 |
Why?
|
| Tuberculin Test | 1 | 2017 | 120 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 309 | 0.120 |
Why?
|
| Survival Rate | 5 | 2021 | 2127 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2017 | 175 | 0.120 |
Why?
|
| Latent Tuberculosis | 1 | 2017 | 75 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 322 | 0.120 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 981 | 0.120 |
Why?
|
| Smoking | 3 | 2019 | 919 | 0.120 |
Why?
|
| Liver Function Tests | 2 | 2014 | 98 | 0.120 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 63 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 300 | 0.120 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 390 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 613 | 0.110 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 354 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 364 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 376 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2017 | 295 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2017 | 448 | 0.110 |
Why?
|
| ROC Curve | 2 | 2021 | 612 | 0.110 |
Why?
|
| Mortality | 1 | 2016 | 260 | 0.110 |
Why?
|
| Stomach | 2 | 2007 | 272 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 142 | 0.110 |
Why?
|
| Medical History Taking | 2 | 2016 | 109 | 0.110 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 1377 | 0.110 |
Why?
|
| Databases as Topic | 2 | 2011 | 75 | 0.100 |
Why?
|
| Intensive Care, Neonatal | 1 | 2014 | 56 | 0.100 |
Why?
|
| Data Collection | 4 | 2023 | 371 | 0.100 |
Why?
|
| Risk Adjustment | 2 | 2021 | 57 | 0.100 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2005 | 92 | 0.100 |
Why?
|
| Ultrasonography | 3 | 2018 | 956 | 0.100 |
Why?
|
| Viremia | 2 | 2011 | 131 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 578 | 0.100 |
Why?
|
| Hepatitis | 1 | 2013 | 57 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 500 | 0.100 |
Why?
|
| Endoscopy | 2 | 2012 | 269 | 0.100 |
Why?
|
| Obesity, Abdominal | 1 | 2013 | 40 | 0.100 |
Why?
|
| Parkinson Disease | 1 | 2020 | 726 | 0.100 |
Why?
|
| Fructose | 1 | 2013 | 61 | 0.100 |
Why?
|
| Subcutaneous Fat | 1 | 2013 | 33 | 0.100 |
Why?
|
| Waist-Hip Ratio | 1 | 2012 | 54 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1159 | 0.090 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2014 | 168 | 0.090 |
Why?
|
| Dietary Carbohydrates | 1 | 2013 | 108 | 0.090 |
Why?
|
| Intra-Abdominal Fat | 1 | 2013 | 63 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 71 | 0.090 |
Why?
|
| Early Detection of Cancer | 4 | 2020 | 419 | 0.090 |
Why?
|
| Renin-Angiotensin System | 2 | 2023 | 106 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 191 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2013 | 190 | 0.090 |
Why?
|
| Current Procedural Terminology | 1 | 2011 | 5 | 0.090 |
Why?
|
| Health Services Administration | 1 | 2011 | 8 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1595 | 0.090 |
Why?
|
| Esophagus | 2 | 2011 | 233 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2013 | 291 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2013 | 228 | 0.090 |
Why?
|
| Spironolactone | 1 | 2011 | 20 | 0.090 |
Why?
|
| Coinfection | 1 | 2013 | 187 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2008 | 258 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2013 | 277 | 0.090 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2014 | 343 | 0.080 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2011 | 45 | 0.080 |
Why?
|
| Cause of Death | 3 | 2016 | 505 | 0.080 |
Why?
|
| Biomarkers | 4 | 2018 | 3388 | 0.080 |
Why?
|
| Likelihood Functions | 1 | 2010 | 117 | 0.080 |
Why?
|
| Calibration | 1 | 2010 | 94 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2021 | 150 | 0.080 |
Why?
|
| Health Facilities | 1 | 2010 | 67 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 1291 | 0.080 |
Why?
|
| Risk | 3 | 2020 | 725 | 0.080 |
Why?
|
| Diphosphonates | 1 | 2010 | 41 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 227 | 0.080 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2010 | 66 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2083 | 0.080 |
Why?
|
| Managed Care Programs | 1 | 2009 | 55 | 0.070 |
Why?
|
| Family Health | 1 | 2010 | 242 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2013 | 556 | 0.070 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 831 | 0.070 |
Why?
|
| Guideline Adherence | 2 | 2011 | 392 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2021 | 6451 | 0.070 |
Why?
|
| Health Services Research | 1 | 2010 | 179 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2013 | 600 | 0.070 |
Why?
|
| Disease Progression | 3 | 2026 | 2204 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2025 | 1297 | 0.070 |
Why?
|
| Stroke Volume | 1 | 2011 | 542 | 0.070 |
Why?
|
| Heart Failure | 3 | 2016 | 2335 | 0.070 |
Why?
|
| Inpatients | 1 | 2013 | 559 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 1 | 2009 | 153 | 0.070 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 3041 | 0.070 |
Why?
|
| Sex Factors | 3 | 2019 | 1343 | 0.070 |
Why?
|
| Motor Activity | 1 | 2010 | 494 | 0.070 |
Why?
|
| Cardia | 1 | 2007 | 26 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 982 | 0.060 |
Why?
|
| Comorbidity | 3 | 2020 | 1584 | 0.060 |
Why?
|
| Patient Selection | 1 | 2010 | 720 | 0.060 |
Why?
|
| Military Personnel | 1 | 2009 | 210 | 0.060 |
Why?
|
| Adolescent | 9 | 2023 | 20739 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 764 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 343 | 0.060 |
Why?
|
| Peptic Ulcer | 2 | 2006 | 151 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 130 | 0.060 |
Why?
|
| Medicare | 3 | 2018 | 438 | 0.060 |
Why?
|
| Esophagoscopy | 1 | 2006 | 174 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2026 | 248 | 0.060 |
Why?
|
| Platinum | 1 | 2025 | 13 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2010 | 711 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2005 | 32 | 0.060 |
Why?
|
| Infliximab | 2 | 2017 | 63 | 0.060 |
Why?
|
| Smoke | 1 | 2025 | 80 | 0.050 |
Why?
|
| Fundoplication | 1 | 2005 | 70 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 646 | 0.050 |
Why?
|
| Fournier Gangrene | 1 | 2004 | 2 | 0.050 |
Why?
|
| Cytokines | 2 | 2021 | 1342 | 0.050 |
Why?
|
| Obesity | 4 | 2022 | 2383 | 0.050 |
Why?
|
| Famous Persons | 1 | 2004 | 14 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 336 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2005 | 150 | 0.050 |
Why?
|
| Neoplasms | 1 | 2018 | 2955 | 0.050 |
Why?
|
| Texas | 3 | 2021 | 3640 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 90 | 0.050 |
Why?
|
| Morbidity | 1 | 2024 | 259 | 0.050 |
Why?
|
| Age Distribution | 3 | 2013 | 424 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 897 | 0.050 |
Why?
|
| Musculoskeletal Diseases | 1 | 2003 | 54 | 0.050 |
Why?
|
| Bipolar Disorder | 1 | 2005 | 346 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2022 | 32 | 0.050 |
Why?
|
| Drug Costs | 1 | 2002 | 63 | 0.050 |
Why?
|
| Tenofovir | 1 | 2022 | 26 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 4023 | 0.040 |
Why?
|
| Young Adult | 4 | 2021 | 10010 | 0.040 |
Why?
|
| Guanine | 1 | 2022 | 59 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2013 | 272 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 2021 | 61 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2003 | 348 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2021 | 123 | 0.040 |
Why?
|
| Demography | 2 | 2016 | 238 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 179 | 0.040 |
Why?
|
| Spain | 1 | 2021 | 59 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 305 | 0.040 |
Why?
|
| Italy | 1 | 2021 | 114 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 138 | 0.040 |
Why?
|
| Virus Internalization | 1 | 2021 | 58 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 419 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2021 | 66 | 0.040 |
Why?
|
| Intraocular Pressure | 1 | 2021 | 134 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 350 | 0.040 |
Why?
|
| Ferritins | 1 | 2021 | 107 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2020 | 31 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 60 | 0.040 |
Why?
|
| Pain | 1 | 2003 | 429 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 1168 | 0.040 |
Why?
|
| Hernia, Hiatal | 2 | 2012 | 57 | 0.040 |
Why?
|
| Weight Gain | 1 | 2022 | 382 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2013 | 483 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 208 | 0.040 |
Why?
|
| Osteoarthritis, Knee | 1 | 2003 | 277 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 115 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1226 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2005 | 727 | 0.040 |
Why?
|
| Leukocytes | 1 | 2020 | 208 | 0.040 |
Why?
|
| Recurrence | 2 | 2017 | 1472 | 0.040 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2018 | 39 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2019 | 84 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 7 | 0.040 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 5 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 505 | 0.030 |
Why?
|
| Body Weight | 1 | 2022 | 987 | 0.030 |
Why?
|
| Anxiety | 1 | 2005 | 1007 | 0.030 |
Why?
|
| Edible Grain | 1 | 2018 | 43 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 59 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 113 | 0.030 |
Why?
|
| Protective Factors | 1 | 2018 | 93 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 760 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 153 | 0.030 |
Why?
|
| Adiponectin | 1 | 2018 | 123 | 0.030 |
Why?
|
| Postmenopause | 1 | 2018 | 136 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 585 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 3711 | 0.030 |
Why?
|
| Certolizumab Pegol | 1 | 2017 | 8 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 617 | 0.030 |
Why?
|
| Adalimumab | 1 | 2017 | 22 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2018 | 110 | 0.030 |
Why?
|
| Helicobacter pylori | 2 | 2019 | 1369 | 0.030 |
Why?
|
| Leptin | 1 | 2018 | 216 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 308 | 0.030 |
Why?
|
| Fruit | 1 | 2018 | 229 | 0.030 |
Why?
|
| Lipids | 1 | 2020 | 561 | 0.030 |
Why?
|
| Metaplasia | 2 | 2007 | 217 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 47 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 939 | 0.030 |
Why?
|
| Depression | 1 | 2005 | 1317 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 254 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 442 | 0.030 |
Why?
|
| Vegetables | 1 | 2018 | 267 | 0.030 |
Why?
|
| Biopsy | 2 | 2011 | 1248 | 0.030 |
Why?
|
| Esophagitis | 2 | 2006 | 38 | 0.030 |
Why?
|
| Reference Values | 2 | 2007 | 680 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2002 | 899 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 371 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 511 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 193 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1817 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2012 | 12 | 0.020 |
Why?
|
| Gastritis | 2 | 2007 | 374 | 0.020 |
Why?
|
| Diet | 1 | 2019 | 1101 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 362 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 596 | 0.020 |
Why?
|
| Ribavirin | 1 | 2011 | 86 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 92 | 0.020 |
Why?
|
| Coffee | 1 | 2010 | 29 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 277 | 0.020 |
Why?
|
| Colon | 1 | 2012 | 361 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2011 | 239 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2014 | 8518 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 890 | 0.020 |
Why?
|
| Trachea | 1 | 2011 | 207 | 0.020 |
Why?
|
| Child | 4 | 2013 | 26100 | 0.020 |
Why?
|
| Helicobacter Infections | 2 | 2013 | 1309 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2010 | 218 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2012 | 698 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 500 | 0.020 |
Why?
|
| Pyloric Antrum | 1 | 2007 | 63 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1628 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2007 | 38 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3751 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2006 | 13 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2006 | 11 | 0.020 |
Why?
|
| Intestinal Polyps | 1 | 2006 | 29 | 0.020 |
Why?
|
| Enema | 1 | 2006 | 46 | 0.020 |
Why?
|
| Occult Blood | 1 | 2006 | 32 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 35 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 681 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 32 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 43 | 0.020 |
Why?
|
| Manometry | 1 | 2006 | 73 | 0.020 |
Why?
|
| Prejudice | 1 | 2006 | 40 | 0.020 |
Why?
|
| Pressure | 1 | 2006 | 122 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 152 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 776 | 0.010 |
Why?
|
| Sleep Deprivation | 1 | 2005 | 44 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2005 | 87 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 938 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 193 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 307 | 0.010 |
Why?
|
| Israel | 1 | 2004 | 48 | 0.010 |
Why?
|
| History, Ancient | 1 | 2004 | 53 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2007 | 493 | 0.010 |
Why?
|
| Life Style | 1 | 2007 | 446 | 0.010 |
Why?
|
| Jews | 1 | 2004 | 34 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 2004 | 82 | 0.010 |
Why?
|
| Memory Disorders | 1 | 2005 | 203 | 0.010 |
Why?
|
| Infant | 2 | 2011 | 13234 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 1480 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 482 | 0.010 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2002 | 14 | 0.010 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2002 | 19 | 0.010 |
Why?
|
| Misoprostol | 1 | 2002 | 24 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2011 | 14946 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 715 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2002 | 177 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 742 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 1236 | 0.010 |
Why?
|
| Alcoholism | 1 | 2002 | 244 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 548 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2004 | 472 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2002 | 403 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2002 | 485 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1880 | 0.010 |
Why?
|
| Quality of Life | 1 | 2005 | 2083 | 0.010 |
Why?
|